Dolutegravir drug for virologic suppression
2018-7-10 dolutegravir is not an inducer or inhibitor of cyp450 or uridine diphosphate glucuronosyltransferase enzymes and therefore is associated with few drug interactions other than metformin and dofetilide dolutegravir should be administered 2 h before or 6 h after taking supplements containing calcium or iron or magnesium containing antacids. Dolutegravir is a human immunodeficiency virus integrase strand transfer inhibitor the mechanism of action of dolutegravir is as a hiv integrase inhibitor, and multidrug and toxin extrusion transporter 1 inhibitor, and organic cation transporter 2 inhibitor. 2018-2-8 viiv healthcare launches eighth phase iii study in two-drug regimen programme for hiv-1 treatment tango study will investigate dolutegravir (tivicay) and lamivudine (epivir) in patients with hiv who have achieved viral suppression on a tenofovir alafenamide fumarate-based regimen.
2018-7-9 juluca® (dolutegravir and rilpivirine) approved in us as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed hiv-1 infection. August 2014 drug dolutegravir (tivicay) indication used in combination with other antiretroviral agents for the treatment of hiv infection in adults and children 12 years of age and older and. 2017-10-26 • the primary outcome was the proportion of patients who maintained virologic suppression (hivrna 50 copies/ml) at the last follow-up visit • adverse events after switch were recorded.
Virologic suppression rates were similar between treatment arms drug related adverse events and adverse events leading to withdrawal occurred in low frequencies in both arms of the study, but more frequently in the investigational arm. Abstract dolutegravir, second generation integrase inhibitor: a new hope for hiv patients author(s): geeta yadav, piyush kumar undeterred efforts have been made and will be made in future to make it possible for hiv-infected individuals to achieve the goals of virologic suppression and one more addition to this rigorous exercise is dolutegravir drug. 2015-2-27 response to a dolutegravir-based regimen in an hiv-infected woman with multiple comorbidities and a highly resistant strain amedeo capetti 1,, laura carenzi 1, noemi astuti 1, valeria cozzi 2, valeria micheli 3, maria vittoria cossu 1 1 1st division of infectious diseases, luigi sacco university hospital, milano, italy 2 clinical.
Dolutegravir retains activity despite the presence of some class-resistant mutations and achieves rapid and sustained virologic suppression in arv-naive and arv-experienced patients clinically, dolutegravir is poised to become a commonly used component of antiretroviral regimens. Drug–drug interactions dolutegravir is a substrate for the efflux transporters p glycoprotein and the human breast cancer resistance protein, but it has high membrane permeability, which reduces the effects that transporters will. 2017-4-14 in recent years, a number of studies have evaluated 2-drug or even 1-drug arv regimens, either in initial therapy or in switch regimens for patients with virologic suppression on 3-drug therapy in general, these have not been as successful in achieving or maintaining virologic suppression as.
A dual therapy based on dolutegravir plus lamivudine could be an intriguing simplification strategy for individuals with stable hiv suppression on cart results: seven studies of dual therapy regimens based on dolutegravir plus lamivudine were critiqued all of them report a low rate of therapeutic failure due to any cause and a small number of. 2018-4-27 lamivudine, drug interactions due to inhibition of oct1 are unlikely to be of clinical sign ificance although abacavir and lamivudine are substrates of bcrp and p-gp in vitro, given the high absolute bioavailability of abacavir and lamivudine, inhibitors of these efflux transporters are unlikely to result in a clinically relevant impact on. 2018-1-19 phase 3 clinical results show an oral, two-drug antiretroviral therapy (art) of dolutegravir and rilpivirine to be an effective and safe alternative to a triple-drug current antiretroviral regimen (car) for maintaining virologic suppression of hiv-1 in adults.
2015-10-24 simplification to dolutegravir monotherapy maintains virologic suppression at week 24 in 2 observational pilot studies neat 001 substudy: no difference in cognitive function with first-line nrti-sparing regimen vs standard art at week 96. 2018-1-22 dolutegravir and abacavir–lamivudine for hiv-1 infection n engl j med 36919 nejmorg 7november , 2013 1809 which participants received dolutegravir at a dose of 50 mg as a separate tablet and abacavir–lami . 2017-2-14 sustained virologic suppression found with switch to two-drug hiv combination february 14, 2017 caitlyn fitzpatrick among a considerable number of phase 3 trial results revealed at the conference on retroviruses and opportunistic infections in seattle, washington is one in which researchers switched patients with hiv from three- or four-drug regimens to two-drug. Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of hiv christopher e kandel,1 sharon l walmsley1,21department of medicine, university of toronto, toronto, on, canada 2division of infectious diseases, university health network, toronto, on, canadaabstract: dolutegravir is the newest integrase strand.
Juluca is a 2-drug regimen, once-daily, single pill that combines the insti dolutegravir (50mg), with the nnrti rilpivirine (25mg) taken once-daily as a complete hiv regimen for people living with hiv who are virologically suppressed. 2018-5-9 the antiretroviral strategy to promote improvement and reduce exposure (aspire) study investigated the efficacy of dolutegravir plus lamivudine to maintain virologic suppression as compared to standard 3-drug art 4 the study was an open-label, randomized, multicenter trial of participants who were 18 years or older, had been on standard 3-drug. 2018-5-18 for virologically suppressed adult patients with hiv-1 the art of two the only single-pill, 2-drug regimen with the power of dolutegravir at the core hiv-1 rna 50 copies/ml on a stable antiretroviral therapy for at least 6 months. 2015-11-7 drug resistance emerging during therapy with dolutegravir and other integrase inhibitors safety signal at least three bc patients have developed new integrase resistance mutations affecting dolutegravir and/or raltegravir and elvitegravir which emerged during treatment with dolutegravir 50 mg daily plus abacavir.
2017-6-21 secondary end points were maintaining virologic suppression in the follow-up (weeks 48 and 96) and safety one hundred and thirty subjects were followed for a median of 56 months reasons for switching were simplification (446%), viral failure (30%), toxicity (169%), non-adherence (46%), persistent low-level viremia (31%), and drug-drug. 2017-3-8 phase iii sword 1&2: switch to dtg+rpv maintains virologic suppression through 48 wks josepm llibre, chien. Duration of virologic suppression is an important factor to consider before modifying an antiretroviral regimen, particularly if there is a need to use regimens of lower potency, lower genetic barrier to resistance, or monotherapy with a boosted pi.